In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
News|Articles|August 2, 2024
Dermatology Month in Review: July 2024
Author(s)Tim Smith
In this Month in Review, the editorial team highlights major news covered in the field of dermatology, including FDA approvals, interviews, and new findings on drugs in the pipeline.
Advertisement
Advertisement
The field of dermatology has seen a variety of new developments in the first half of 2024, and the month of July alone has been a significant time for research and other news in this space.
Related to this article
In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
The FDA has granted Priority Review to dersimelagon for EPP and XLP, setting a PDUFA date for late February 2027 as LEO Pharma completes its acquisition from Tanabe Pharma.
Neal Bhatia, MD, weighs the newly approved Ameluz PDT regimen for sBCC against Mohs surgery, citing its 66% composite response rate.
Advertisement
Advertisement